search
Back to results

Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia

Primary Purpose

Leukemia, Acute

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
posaconazole oral suspensions
Sponsored by
Zhujiang Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia, Acute

Eligibility Criteria

2 Years - 14 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 1、Patients age 2-14 years with acute leukemia (AML, ALL) undergoing chemotherapy and neutropenia expected to last at least 7 days.

    2、Karnofsky/Lansky score of 60% or greater. 3、defined as alanine transaminase (ALT) <3 x upper limit of normal (ULN),aspartate aminotransferase (AST) <3 x ULN; serum bilirubin and alkaline phosphatase <2 x ULN.

    4、No other treatment and combination of triazoles antifungals and drugs like vincristine, sirolimus, cyclosporine etc.

    5、Able to take oral medication or take medication via enteral feeding tube. 6、Ability to give informed consent. 7、No history of anaphylaxis attributed to the azole class of antifungal agents.

Exclusion Criteria:

  • 1、Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction.

    2、Subject is not considered eligible for this clinical research program with posaconazole.

    3、Use of medications that are known to interact with posaconazole and that may lead to life-threatening side to effects.

Sites / Locations

  • Zhujiang Hospital of Southern Medical University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

posaconazole as antifungal prophylaxis

Arm Description

Outcomes

Primary Outcome Measures

Number, type and grade of adverse events of posaconazole assessed by CTCAE v4.0
Number, type and grade of adverse events of posaconazole oral suspensions to children with leukemia assessed by CTCAE v4.0.
Plasma posaconazole concentration monitoring and its pharmacokinetic
Blood samples for determination of plasma posaconazole concentration will be collected predoses (just prior to a daily dose) on days 3, 7, 14 and 21. Anther concentration (include peak concentraton) will also be collected at least 7days after the first dose.

Secondary Outcome Measures

Serious Adverse events and drug-related adverse events monitoring

Full Information

First Posted
October 19, 2019
Last Updated
August 2, 2021
Sponsor
Zhujiang Hospital
Collaborators
Guangdong Provincial People's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04194086
Brief Title
Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia
Official Title
Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
July 1, 2021 (Actual)
Study Completion Date
July 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhujiang Hospital
Collaborators
Guangdong Provincial People's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study is designed to evaluate the safety, efficacy and Population Pharmacokinetics of Oral Posaconazole in Children with leukemia.
Detailed Description
Posaconazole as a new triazole antifungal agent with broad spectrum coverage, was recommended for prophylaxis of invasive fungal disease in adults. Some studies have demonstrated the relationship between posaconazole plasma concentration and efficacy and few data have been published in children with leukemia.The purpose of this study is to describe the off-label use of posaconazole oral suspensions in children;to figure out the relationship between concentration and clinical outcomes/ adverse events;to identify factors that influence plasma concentration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia, Acute

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
posaconazole as antifungal prophylaxis
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
posaconazole oral suspensions
Intervention Description
posaconazole oral suspensions(5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
Primary Outcome Measure Information:
Title
Number, type and grade of adverse events of posaconazole assessed by CTCAE v4.0
Description
Number, type and grade of adverse events of posaconazole oral suspensions to children with leukemia assessed by CTCAE v4.0.
Time Frame
1 year
Title
Plasma posaconazole concentration monitoring and its pharmacokinetic
Description
Blood samples for determination of plasma posaconazole concentration will be collected predoses (just prior to a daily dose) on days 3, 7, 14 and 21. Anther concentration (include peak concentraton) will also be collected at least 7days after the first dose.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Serious Adverse events and drug-related adverse events monitoring
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1、Patients age 2-14 years with acute leukemia (AML, ALL) undergoing chemotherapy and neutropenia expected to last at least 7 days. 2、Karnofsky/Lansky score of 60% or greater. 3、defined as alanine transaminase (ALT) <3 x upper limit of normal (ULN),aspartate aminotransferase (AST) <3 x ULN; serum bilirubin and alkaline phosphatase <2 x ULN. 4、No other treatment and combination of triazoles antifungals and drugs like vincristine, sirolimus, cyclosporine etc. 5、Able to take oral medication or take medication via enteral feeding tube. 6、Ability to give informed consent. 7、No history of anaphylaxis attributed to the azole class of antifungal agents. Exclusion Criteria: 1、Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction. 2、Subject is not considered eligible for this clinical research program with posaconazole. 3、Use of medications that are known to interact with posaconazole and that may lead to life-threatening side to effects.
Facility Information:
Facility Name
Zhujiang Hospital of Southern Medical University
City
Guanzhou
State/Province
Guangdong
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia

We'll reach out to this number within 24 hrs